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Research on the genetics of smoking has increased our
understanding of nicotine dependence, and it is likely to
illuminate the mechanisms by which cigarette smoking
adversely effects the health of smokers. Given recent
advances in molecular biology, including the completion
of the draft sequence of the human genome, interest has
now turned to identifying gene markers that predict a
heightened risk of using tobacco and developing
nicotine dependence
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Thanks to RA Fisher, genetics has been linkedto scepticism about a causal relation betweencigarette smoking and lung cancer.1 2 Fisher3
argued that the association between smoking and
lung cancer was explained by shared genes that
predisposed people to initiate smoking as young
adults and to develop lung cancer in late
adulthood. Much use was made of his hypothesis
by the tobacco industry to manufacture a
spurious controversy about the health effects of
smoking, a fact that may have discouraged public
health research into the genetic contribution to
smoking.1
Over the past decade, research on the genetics
of tobacco use has strongly suggested that genetic
factors do play a role in different stages of tobacco
use and dependence. Given the possible misuse
and misunderstanding of this work, it is impor-
tant for researchers and policy makers in the
tobacco field to be acquainted with the research
and its policy implications. Our aims are accord-
ingly: (1) to summarise the results of recent
research on the genetics of tobacco use from
adoption, twin, linkage, and association studies;
and (2) to consider the implications of these
findings for public health and tobacco control
policies.
GENETIC STUDY DESIGNS AND
RESEARCH FINDINGS
Traditional family studies suggest that genetic
factors influence smoking by reporting elevated
rates of tobacco use and dependence in the
relatives of people who smoke tobacco. For exam-
ple, Niu and colleagues4 reported that individuals
with a nicotine dependent sibling were 2.1–3.5
times more likely to be nicotine dependent
(defined by Fagerstrom score and the revised tol-
erance questionnaire) than those who did not.
Such studies, however, confound genetic and
environmental influences because siblings share
environmental influences as well as genes.
Specific study designs—adoption, twin, and link-
age designs—are needed to separate the effects of
genes from those of the environment.
Adoption studies
In the adoption design we compare the similarity
in smoking between adoptive children and their
biological parents with the similarity between
adopted children and their adoptive parents or
between adoptive sibling pairs and biological sib-
ling pairs. If smoking is largely or wholly geneti-
cally determined, then there should be greater
similarity between children and their biological
parents and siblings than between adopted
children and their adoptive parents or siblings.
One early adoption study found an association
between the smoking of foster children and their
biological siblings but not their adoptive
siblings.5 A recent adoption study6 reported mod-
erate to strong associations between adoptees’
smoking and that of their biological siblings, and
between male adoptees’ and their biological
mothers’ smoking.
It has become increasingly difficult to conduct
adoption studies because fewer children are
available for adoption except transnationally and
there are ethical concerns about such studies. The
older studies often lacked detailed information on
biological parents and the placement of adoptees
(usually to more advantaged homes) restricted
variation in the environments to which they were
exposed. Adoption studies also had a limited abil-
ity to assess the role of family environment
because in some countries the practice was to
match biological and adoptive parents on key
demographic features (for example, education or
religious affiliation), introducing a correlation
between genes and environment. Finally, adop-
tion studies that included subjects who were not
adopted immediately at birth may have overesti-
mated genetic effects by attributing the effects of
early environmental exposures to genetic
influences.7
Twin studies
The twin study method compares the agreement
in the behaviour of (1) monozygotic or identical
twins who share the same genetic make-up, and
(2) dizygotic or fraternal twins who share on
average 50% of their genetic make up, the same as
ordinary siblings. Twins are said to be “concord-
ant” if both engage in the same behaviour (for
example, both smoke tobacco). If certain assump-
tions are met (see below), a higher rate of agree-
ment in monozygotic than dizygotic twins can be
attributed to genetic factors. Statistical models
estimate the percentage of variance in the trait
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that is explained by genes (heritability) and by shared (expe-
riences shared by family members) and non-shared (experi-
ences unique to the individual) environment.
The results of a number of large scale twin studies of ciga-
rette smoking from around the world are summarised in table
1.9–17 The data presented in this table are the result of a
re-analysis of data from the original studies.8 The top half of
the table provides the results of eight studies that have exam-
ined genetic and environmental influences on smoking initia-
tion; the bottom half summarises twin studies of smoking
persistence.
Because the reported prevalence of smoking initiation was
not high in these studies (all substantially lower than 90%) we
can assume that “smoking initiation” generally referred to the
initiation of “regular”, usually daily cigarette smoking. In fact,
most of the Scandinavian studies of smoking initiation
defined people who smoked less than 100 cigarettes in their
lives as non-smokers. Despite the wide range of cultures, ages,
and birth cohorts represented in these papers, estimates of the
heritability of smoking initiation were substantial for both
men and women: they ranged between 37%11 and 84%12 in
women and between 28%12 and 84%12 in men (see original
papers for details). By contrast, there was little consistency
between studies for the importance of family environment. In
some studies, shared family environment was estimated to
account for 50%11 of the variance in smoking initiation among
women and 49%17 of the variance among men. Yet other
studies11 12 reported no significant shared environmental
influences on smoking initiation.
Findings from some8 15 17 but not all studies of smoking
persistence5 18 suggest that some genetic and environmental
influences are specific to smoking persistence while there are
some shared genetic and environmental influences on smok-
ing persistence and smoking initiation. Analyses conducted by
Madden and her colleagues19 suggest that the degree of over-
lap in genetic contribution to smoking initiation and
persistence may vary with age and sex. Other studies have
confirmed that both genetic and environmental influences
play an important role in nicotine dependence.20–22
A critical assumption of the twin study method is that
monozygotic and dizygotic twins have equal exposures to
environmental influences that affect the trait under study (the
“equal environments assumption”). If this assumption is not
met (for example, because monozygotic twins have more
similar environments than dizygotic twins), then twin studies
provide inflated estimates of genetic influences on behaviour.
Research has generally,23–27 although not always,28 supported
the validity of the equal environments assumption in studies
of substance use. This has included studies of twin pairs who
were misinformed about their zygosity23 24 and retrospective
reports of childhood and adult social environments in mono-
zygotic and dizygotic twins.25–28
The traditional twin method also assumes that the environ-
ments of twins and singleton siblings are comparable. This
assumption may not hold because twins have higher rates of
obstetric complications and low birth weight than singleton
births and there are different patterns of family and sibling
interactions in families with twins than in those without.7
A final limitation of the twin study is that it has low statis-
tical power to test for gene–environment interactions and
gene–environment correlation effects in the aetiology of
smoking and other behaviours. Some of these problems can be
addressed using extensions of the twin design, including the
study of the children of twins and other family members.7 29
For example, studies of the offspring of monozygotic twins
who are discordant for smoking provide a powerful way of
disentangling genetic and environmental effects because the
offspring of the discordant monozygotic twins share the same
genetic relationship to both twins but are exposed to different
family environments. These designs have yet to be applied to
the study of smoking behaviour and nicotine dependence.
Studies of twins reared apart
The study of twins reared apart is a powerful research design
that combines aspects of twin and adoption studies. This
design enables one to separate genetic effects from environ-
mental effects because monozygotic twins reared apart share
the same genes but different environments. Greater concord-
ance in behaviour among monozygotic than dizygotic twins
reared apart provides strong support for a genetic contribution
to smoking.
There have been five studies of smoking in twins reared
apart.3 10 29–32 The most recent, and the most methodologically
rigorous,32 concluded that 60% of the variance in regular
tobacco use among men and among women born after 1940
could be explained by genetic factors. In women born earlier
in the century, rates of regular tobacco use were substantially
lower and modelling suggested that shared environmental
effects largely accounted for twin resemblance in these
women.
Table 1 Estimates from twin studies of genetic (A), shared environmental (C), and
non-shared environmental (E) influences on smoking initiation and persistence in
women and men
Women Men
A C E A C E
Initiation
Sweden9 44 42 14 51 39 10
Denmark10 79 – 21 84 – 16
Finland11 37 50 13 50 33 17
Australia12 77 4 19 28 43 29
Australia13 60 26 14 80 – 20
USA second world war veterans14 – – – 59 21 20
USA Virginia12 84 – 16 84 – 16
USA Vietnam veterans15 – – – 39 49 12
Persistence
Sweden9 59 – 41 52 – 48
Finland16 71 – 29 68 – 32
Australia17 53 – 47 53 – 47
Australia13 62 – 38 62 – 38
USA8 58 – 42 58 – 42
USA Vietnam veterans15 – – – 69 – 31
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Summary of twin and adoption studies
Despite the limitations in each of the experimental designs
described above, there is strong support for genetic factors
playing a role (along with environment) in tobacco smoking
and nicotine dependence. This comes from the consistency of
findings between twin studies and the convergence of results
from the very different study designs. Given recent advances
in molecular biology, including the completion of the draft
sequence of the human genome,33 interest has now turned to
identifying gene markers that predict a heightened risk of
using tobacco and developing nicotine dependence.
Linkage studies
A number of aspects of an individual’s response to nicotine
could have important effects on smoking. For example,
individuals may vary in their sensitivity to nicotine’s effects,
the rate at which they develop tolerance to its effects, and in
the severity of withdrawal symptoms if they stop smoking.
These are likely to have a biological basis although this is as yet
poorly understood.34
An important recent development has been the use of gene
mapping methods to study tobacco use. Gene mapping identi-
fies genes that predict a trait or disorder. The identification is
empirical in that it is not based on prior knowledge of a gene’s
function, but is discovered by studying whether smoking is
co-inherited with markers found in specific chromosomal
regions. Positive reports of genetic linkage for alcohol related
behaviours are beginning to emerge35–37 although as yet very
few have been replicated.
Traditional methods of linkage analysis, which study
co-inheritance within families (“pedigrees”), have been
useful in mapping single gene dominant, recessive or x linked
disorders. Typically large pedigrees containing multiple
affected family members have been studied, sometimes over
several generations.38 These studies test specific models for the
inheritance of the disorder. It is difficult to use these
traditional methods of linkage to study the genetics of smok-
ing and other complex traits in which multiple genes probably
play a role (that is, polygenic disorders and traits). In these
cases, it has proven more difficult to replicate the genetic link-
ages than to find candidate regions of chromosomes. This is
because the classical linkage method requires large pedigrees
in which a single or, at most, only a few, risk increasing genes
are assumed to be segregating. We also need to know (or
guess) whether the genes involved in these disorders are hav-
ing dominant, additive or recessive effects, which we typically
do not know for complex behaviours such as smoking.
In studying the genetics of smoking it has become standard
to use affected relative or allele sharing methods of
analysis.39 40 These methods avoid the difficulty of defining
“unaffected” individuals for complex behaviours such as
smoking. It uses the nuclear family as the sampling unit to
minimise the analytical problems that arise from the accumu-
lation of multiple susceptibility genes in extended pedigrees.
Typically, families with two or more affected siblings are iden-
tified, and the affected siblings and,whenever possible, both of
their biological parents are genotyped. If a gene in a particular
chromosomal region is associated with smoking, and if a
genetic marker is in close proximity (that is, linked), then the
affected siblings will be more likely to share the same mater-
nal and/or paternal marker genes. In the absence of parental
data there is a loss of statistical power41 that is only partially
addressed by using multiple markers.
Candidate genes for nicotine dependence
There are a number of plausible “candidate genes” for nicotine
dependence—that is, genes that affect an individual’s vulner-
ability to developing nicotine dependence. These include poly-
morphism (variants of genes) that metabolise nicotine in
ways that may reduce the likelihood of smoking (for example,
Pianezza and colleagues,42 but see Oscarson and associates43
for subsequent work suggesting that the original report was
flawed because of genotyping errors). Another promising
group of candidate genes code for dopamine receptors and
transporters,44 45 the neurotransmitter system that mediates
reward in the nucleus acumbens of the midbrain.46 Studies
have identified associations between smoking and some of
these candidate genes, but for a number of reasons these
associations have not been consistently replicated to date.46 47
The following factors contribute to the difficulty in finding
reproducible associations between candidate genes and
nicotine dependence. One is the multiple comparison prob-
lem: in searching for associations between smoking and a
large number of candidate genes, there will be false positive
associations. A second factor is heterogeneity between groups
in the prevalence of these genes, something that may mask
real associations and produce spurious ones in standard case–
control comparisons. A third factor is that it is difficult to
detect multiple genes of modest effect because association and
linkage studies have low statistical power to detect these types
of associations.48 49 A fourth factor is differences between
studies in the definition of a smoker. More work is necessary
to identify measures that most adequately capture liability to
tobacco use and nicotine dependence. These difficulties are
not insurmountable so larger, better controlled studies of a
smaller set of candidate genes will probably identify genes
that increase the likelihood of developing nicotine depend-
ence.
The fate of Fisher’s sceptical hypothesis
How has Fisher’s hypothesis about genetics of smoking and
lung cancer fared in the light of recent genetic research?
Research has partially supported Fisher’s hypothesis in
finding a substantial genetic component to smoking initiation
and persistence. There is also some support for the hypothesis
that genetic factors play a role in diseases caused by smoking,
such as cancers generally50 51 and lung cancer in particular,52 53
heart disease,54 and chronic obstructive lung disease.55
However, this genetic research has also undermined the
limited plausibility Fisher’s hypothesis ever had (which was
never very strong when it was first proposed; see the 1964 US
General Surgeon’s report on Smoking and health,56 pages
193–6). The main reason is that the genes that increase the
risks of smoking (for example, genes that regulate nicotine
dependence and the dopamine system) are different from
those that increase the risk of lung cancer (for example, genes
that affect the metabolism of carcinogens in tobacco smoke).
This is contrary to Fisher’s hypothesis which required that the
same genes caused both smoking and lung cancer. An
improved understanding of the biological mechanisms of car-
cinogenesis and cardiovascular disease is also beginning to
provide detailed explanations of the strong associations
observed between cigarette smoking and these diseases (for
example, Humphries and colleagues54). Genetic research on
smoking has therefore made Fisher’s sceptical position on
cigarette smoking and lung cancer no more scientifically cred-
ible than creation science.57
POLICY IMPLICATIONS
Predictive genetic testing for nicotine dependence
Technological optimists58 have argued that the molecular
mapping of the human genome will allow genetic screening of
the population to identify persons at high risk of developing
specific diseases—for example, cancers and heart disease.
These high risk individuals can then be given appropriate
behavioural and pharmacological interventions to prevent
these diseases from occurring. This has been described as
“predictive genetic testing”.59 What are the prospects for pre-
dictive screening to identify those at risk of nicotine
addiction?
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There is one compelling reason why we would not be inter-
ested in predictive testing for nicotine dependence: there is no
public health interest in encouraging people to smoke tobacco,
regardless of their risks of nicotine dependence. Even if this
were not true, there are other good reasons why it would not
be good policy to screen for susceptibility to nicotine
dependence.59
Firstly, predictive testing is most defensible when we screen
for disorders in which a single gene confers a high risk of
developing a serious life threatening disease and when safe
and effective interventions exist.60 When multiple genes and
multiple environmental risk factors predispose to common
diseases, there may be gene–gene or gene–environment inter-
actions, with the result that these genes are “incompletely
penetrant”—that is, a person with these genes has an increased
risk of developing the disease but the absolute probability of
their doing is often still quite small.59 In general, the more
genes that are involved in disease susceptibility, the less useful
to individuals is information about their genotype. Some sim-
ple calculations show that there do not have to be many genes
involved for this to be true.
Let us assume: (1) that there are three genes, each of which
trebles the risk of nicotine dependence (a relative risk of 3);
(2) that each has a frequency of 10% in the population; (3)
that the genes are inherited independently; and (4) that their
risks are multiplicative. There would be 8 possible combina-
tions of genotypes with the prevalences and relative risks
shown in table 2. Most people (72.9% of the population)
would not have any increased risk. Almost a quarter (24.3%)
would have a modest threefold increase in risk. The group
with a ninefold increase in risk would comprise 2.7% of the
population, and only 0.01% of the population would have the
highest risk, a 27-fold increase in risk.
Secondly, given the low prevalence of high risk combina-
tions of susceptibility genes, a very large number of individu-
als would need to be screened to identify those with these
genes. This is expensive and difficult to justify on public health
grounds.61 62
Thirdly, screening is only justifiable if there is an effective
intervention to prevent the disorder in those who possess sus-
ceptibility genes.59 “Avoid smoking” is good advice regardless
of one’s genotype for nicotine dependence. The development
of an effective nicotine vaccine63 would provide more incentive
for screening. But such screening would also raise a different
ethical issue (for example, about the right of parents to vacci-
nate their children). It would also raise serious questions of
public policy—for example, would it be more practicable to
screen and vaccinate or simply to have universal nicotine vac-
cination?Whowould pay the costs of such a programme? How
likely is it that such a programme would be publicly funded in
the face of tobacco industry opposition?
Fourthly, there is a possibility that predictive genetic testing
may also have perverse and unintended effects. For example,
what effects would testing adolescents for susceptibility to
nicotine have on their preparedness to try smoking? What
effects would it have on health insurance and on the social
stigmatisation of those who are at risk?
Predictive genetic testing for tobacco related diseases
The tobacco industry is much more likely to be interested in
screening for genes that increase a smoker’s susceptibility to
smoking related diseases. Its executives may hope that the
identification of susceptibility genes for tobacco related
diseases would enable individuals who lacked these genes to
smoke tobacco “safely”.64 This proposal is even more impracti-
cal from a public health perspective than screening for
susceptibility to nicotine dependence, for several reasons.
Firstly, there is a major problem in making predictions
about disease risks for individuals when, as seems likely, mul-
tiple genes are involved in disease susceptibility. Secondly,
cigarette smoking also causes multiple diseases,with lung and
other cancers, heart disease, and chronic obstructive lung dis-
ease being the most prevalent. Thirdly, the combination of
multiple susceptibility genes andmultiple diseases means that
all smokers will have at least one susceptibility gene for one or
more smoking related diseases.64 The impracticality of such
screening may not prevent the tobacco industry from using
the possibility of this type of screening to reassure ambivalent
smokers that they can continue to smoke. Public health
professionals will therefore need to be well versed in explain-
ing its impracticality.
Better treatment of nicotine dependence
The most likely benefit of research on the genetics of smoking
is an improvement in smoking cessation rates.46 The need to
improve smoking cessation rates will increase because, as the
population prevalence of smoking declines, the proportion of
smokers with multiple genetic predispositions to nicotine
dependence will probably increase, as will the proportion of
smokers with co-morbid mental health problems that make it
difficult to quit.65 Genetic research on smoking may improve
the success of smoking cessation in a number of ways.
Firstly, a better understanding of nicotine dependence may
lead to the development of more effective smoking cessation
drugs. These may include drugs that act on key neural reward
pathways and affect nicotine metabolism. These drugs may
have fewer adverse side effects than existing ones. There may
also be nicotine vaccines to help ex-smokers remain abstinent
by preventing nicotine from acting in the brain.63
Secondly, genotyping of smokers desiring help with
cessation may better match patients to existing cessation
drugs such as, bupropion (Zyban; GlaxoSmithKline),
nortriptyline, and nicotine replacement.46 If, as seems likely,
the prediction of treatment response from individual genes is
modest, actuarial methods (such as multiple regression) will
be needed. Given the expense of genotyping (even with a
reduction in cost with technological improvements), “nicotine
pharmacogenomics” will need to improve upon treatment
matching using smoking behaviour (for example, the Fager-
strom scale or number of previous unsuccessful quit attempts)
and on a policy of not matching by offering all patients the
treatment that, averaged across genotypes, is most effective.
We will also need to consider disadvantages of giving
smokers information about their genetic vulnerability to nico-
tine dependence. Will it, for example, encourage smokers to
believe that their nicotine dependence is intractable?66 We will
need to provide better education about the implications of
genetic information to overcome the mistaken belief that
genetic causation of behaviour means that it cannot be
changed. We need to use easily understood examples, such as
“spectacles can correct shortsightedness even though it is
under partial genetic control”.
Implications for smoking control policies
Smoking control policies aim to reduce the availability of
tobacco by making it expensive by imposing high taxes on
tobacco products and by restricting minors’ access to
tobacco.67 These policies affect the whole community, not just
Table 2 Hypothetical distribution of susceptibility
genes in the population, each with a prevalence of
10% and each carrying a relative risk of disease of
3.0.
Gene combination
None Any one Any two All three
Percentage of
population
72.9 24.3 2.7 0.1
Relative risk 1.0 3.0 9.0 27.0
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those who are at risk of nicotine dependence. One can expect
the tobacco industry to argue that on the grounds of efficiency
and equity tobacco control measures should be focused on
those at highest risk of becoming nicotine dependent.
There are a number of problems with this superficially
attractive argument. Firstly, when multiple genes are impli-
cated in nicotine dependence it is impractical to identify the
small number of individuals at highest risk, as argued above.
Secondly, population screening for nicotine dependence
susceptibility genes is much more expensive than simply tax-
ing tobacco use, protecting minors, and not allowing tobacco
promotion. Thirdly, one does not need to be nicotine depend-
ent to experience adverse health effects from smoking. Hence,
the prevention of nicotine dependence will not prevent other
smoking related diseases.
One can also anticipate the argument that individuals
should be given a choice as to whether they undergo genetic
screening for susceptibility to tobacco related disease. If one
accepts this argument, then the wealthy may choose to be
tested. There would be no case, however, for government
funding or private health insurance coverage for such screen-
ing. The tobacco industry may consider funding such screen-
ing programmes as a potentially useful way of encouraging
smokers to believe that they can reduce the risks of continuing
to smoke.
The tobacco industry has lately developed other interests in
biotechnology. Japan Tobacco has entered into an agreement
with a US biotechnology company to develop and license a
vaccine against lung cancer.68 Presumably the intention is to
offer the vaccine to smokers whowant to continue to smoke so
that they can reduce their chances of developing lung cancer.
There are a number of major objections to this proposal,
even if we ignore the considerable uncertainty about how
effective a vaccine will be in preventing lung cancer in smok-
ers. Firstly, it is arguably unethical for tobacco companies to
profit from preventing a disease of which their product is the
major cause.68 Secondly, because lung cancer is only one of 50
diseases that cigarette smoking causes, reducing this risk will
not eliminate the health risks of cigarette smoking.
CONCLUSIONS
Twin, adoption, and other studies suggest that all stages of
tobacco use and dependence are partially under genetic
control. A number of candidate genes have been identified to
explain this association but none have so far been consistently
replicated. This reflects technical difficulties in doing associ-
ation studies with a behaviour like smoking that is probably
influenced by multiple genetic factors.
Research on the genetics of smoking has increased our
understanding of nicotine dependence and it is likely to
illuminate the mechanisms by which cigarette smoking
adversely effects the health of smokers. Genetic research has
undermined Fisher’s hypothesis that there is a common
genetic cause for cigarette smoking and lung cancer.
The most immediate benefit of work on the genetics of
smoking from a tobacco control perspective may be more
effective drugs to assist smokers to stop smoking. It may allow
better matching of smokers to cessation treatments. Popula-
tion screening for genes that confer susceptibility to nicotine
dependence or smoking related diseases is unlikely to be prac-
tical.
Improved understanding of the genetics of smoking are not
likely to affect public health tobacco control policies. It is much
simpler, cheaper, and more efficient to discourage the whole
population from smoking tobacco than it is to attempt to
make smoking safer by identifying those at highest risk of
nicotine addiction or smoking related disease.
The tobacco industry can be expected to use whatever
opportunities genetics and biotechnology of smoking and
smoking related disease provide to ensure the longevity of
their industry. Public health advocates would therefore be
wise to keep abreast of developments in the genetics of smok-
ing and biomedical innovations in treating smoking related
diseases.
ACKNOWLEDGEMENTS
Supported by NIH grants DA12540, DA12854 (PAFM) from the
National Institute on Drug Abuse and AA07728(ML) from the
National Institute on Alcohol Abuse and Alcoholism. The authors
would like to thank Andrew Heath for helpful comments on an earlier
draft of this paper.
. . . . . . . . . . . . . . . . . . . . .
Authors’ affiliations
W Hall, Office of Public Policy and Ethics, Institute for Molecular
Bioscience, University of Queensland, St Lucia, Queensland 4072,
Australia
P Madden, M Lynskey, Missouri Alcoholism Research Center,
Department of Psychiatry, Washington University School of Medicine, 40
N Kingshighway, Suite One, St Louis, MO 63108, USA
REFERENCES
1 Kozlowski LT. Rehabilitating a genetic perspective in the study of
tobacco and alcohol use. Br J Addiction 1991;86:517–20.
2 Stolley PD. When genius errs: R.A. Fisher and the lung cancer
controversy. Am J Epidemiol 1991;133:416–25.
3 Fisher RA. Cigarettes, cancer and statistics. Centennial Review
1958;2:151–66.
4 Niu T, Chen C, Ni J, et al. Nicotine dependence and its familial
aggregation in Chinese. Int J Epidemiol 2000;29:248–52.
5 Eaves LJ, Eysenck HJ. The genetics of smoking. In: Eysenck HJ, ed. The
causes and effects of smoking. London: Temple-Smith, 1980.
6 Osler M, Holst C, Prescott E, et al. Influence of genes and environment
on adult smoking behavior assessed in an adoption study. Genet
Epidemiol 2001;21:193–200.
7 Rutter M, Pickles A, Murray R, et al. Testing hypotheses on specific
environmental causal effects on behavior. Psychol Bull
2001;127:291–324.
8 Heath AC, Madden PAF. Genetic influences on smoking behavior. In
Turner JR, Cardon LR, Hewitt JK, eds. Behavior genetic approaches in
behavioral medicine. New York: Plenum Press, 1995:45–66.
9 Medlund P, Cederlof R, Floderus-Myrhed R, et al. A new Swedish twin
registry. Acta Med Scand 1977;supplementum 600.
10 Raaschou-Nielsen E. Smoking habits in twins. Danish Medical Bulletin
1960;7:82–8.
11 Kaprio J, Sarna S, Koskenvuo M, et al. The Finnish twin registry:
baseline characteristics. Section II. Helsinki: University of Helsinki Press,
1978.
12 Heath AC, Cates RC, Martin NG, et al. Genetic contribution to risk of
smoking initiation: comparisons across birth cohort and across cultures.
Journal of Substance Abuse 1993;5:221–46.
13 Madden PAF, Heath AC, Bucholz KK, et al. Genetics and smoking.
Paper presented at the 55th annual meeting of the College on Problems
of Drug Dependence. Toronto, Canada, 12–17 June 1993.
14 Carmelli D, Swan GE, Robinette D, et al. Genetic influence on smoking
– a study of male twins. N Engl J Med 1992;327:881–3.
15 True WR, Heath AC, Scherrer JF, et al. Genetic and environmental
contributions to smoking. Addiction 1997;92:1277–87.
16 Kaprio J, Koskenvuo M. A prospective study of psychological and
socio-economic characteristics, health behavior and morbidity in cigarette
smokers prior to quitting compared to persistent smokers and
non-smokers. J Clin Epidemiol 1988;41:139–50.
17 Heath AC, Martin NG. Genetic models for the natural history of
smoking: evidence for a genetic influence on smoking persistence. Addict
Behav 1993;18:19–34.
18 Heath AC. Persist or quit? Testing for a genetic contribution to smoking
persistence. Acta Genet Med Gemellol (Roma) 1990;39:447–58.
19 Madden PAF, Heath AC, Pedersen NL, et al The genetics of smoking
persistence in men and women: a multicultural study. Behav Genet
1999;29:423–31.
20 Prescott CA, Kendler KS. Genetic and environmental influences on
alcohol and tobacco dependence among women. In: JB Fertig, JP Allen,
eds. Alcohol and tobacco: from basic science to clinical practice.
National Institute on Alcohol Abuse and Alcoholism Research,
Monograph No. 30 Bethesda, Maryland: NIAA, 1995:59–87.
21 True WR, Xian H, Scherrer JF, et al. Common genetic vulnerability for
nicotine and alcohol dependence. Arch Gen Psychiatry
1999;56:655–61.
22 Kendler, KS, Neale MC, Sullivan P, et al. A population-based twin study
in women of smoking initiation and nicotine dependence. Psychol Med
1999;29:299–308.
23 Kendler KS, Neale MC, Kessler RC, et al. A test of the equal
environment assumption in twin studies of psychiatric illness. Behav Gen
1993;23:21–7.
24 Kendler KS, Neale MC, Kessler RC, et al. Parental treatment and the
equal environment assumption in twin studies of psychiatric illness.
Psychol Med 1994;24:579–90.
Genetics of tobacco use 123
www.tobaccocontrol.com
25 Kendler KS, Gardner CO. Twin studies of adult psychiatric and
substance dependence disorders: are they biased by differences in the
environmental experiences of monozygotic and dizygotic twins in
childhood and adolescence? Psychol Med 1998;28:625–33.
26 Kendler KS, Heath AC, Neale MC, et al. A population-based twin study
of alcoholism in women. JAMA 1992;268:1877–82.
27 Lynskey MT, Heath AC, Nelson EC, et al. Genetic and environmental
contributions to cannabis dependence in a national young adult twin
sample. Psychol Med (in press).
28 Kaprio J, Koskenvuo M, Langinvainio H, et al. Genetic influences on use
and abuse of alcohol: a study of 5638 adult Finnish twin brothers.
Alcoholism: Clinical and experimental Research 1987;11:349–56.
29 Heath AC, Kendler KS, Eaves LJ, et al. The resolution of biological and
cultural inheritance: Informativeness of different relationships. Behav
Genet 1985;23:29–50.
30 Shields J. Monozygotic twins brought up apart and brought up together.
London: Oxford University Press, 1962.
31 Kaprio J, Koskenvuo M, Langinvainio H. Finnish twins reared apart, IV:
smoking and drinking habits: a preliminary analysis of the effect of
heredity and environment. Acta Genet Med Gemellol (Roma)
1984;33:425–33.
32 Kendler KS, Thornton LM, Pedersen NL. Tobacco consumption in
Swedish twins reared apart and reared together. Arch Gen Psychiatry
2000;57:886–92.
33 International Human Genome Sequencing Consortium. Initial
sequencing and analysis of the human genome. Nature
2001;409:860–921.
34 Pomerleau OF. Individual differences in sensitivity to nicotine:
implications for genetic research on nicotine dependence. Behav Genet
1995;25:161–77.
35 Long JC, Knowler WC, Hanson RL, et al. Evidence for genetic linkage to
alcohol dependence on chromosomes 4 and 11 from an autosome-wide
scan in an American Indian population. Am J Med Genet
1998;81:216–21.
36 Reich T, Edenberg HJ, Goate A, et al. Genome-wide search for genes
affecting the risk for alcohol dependence. Am J Med Genet
1998;81:207–15.
37 Vallejo RL, Wilhelm LA, Hoopes D, et al. Genome wide search for
genes affecting vulnerability to alcohol dependence in Finnish pedigrees.
Am J Human Genet 1998;63:A45.
38 Ott J. Analysis of human genetic linkage, revised ed. Baltimore: Johns
Hopkins University Press, 1991.
39 Lander E, Schork NJ. Genetic dissection of complex traits. Science
1994;265:2037–48.
40 Risch N. Linkage strategies for genetically complex traits. II. The power
of affected relative pairs. Am J Human Genet 1990;46:229–41.
41 Bishop DT, Williamson JA. The power of identity-by-state methods for
linkage analysis. Am J Human Genet 1990;46:254–65.
42 Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect
reduces smoking. Nature 1998;393:750.
43 Oscarson M, Gullsten H, Rautio A, et al. Genotyping of human
cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Letters
1998;438:201–5.
44 Lerman C, Caporaso NE, Audrain J, et al. Evidence suggesting the role
of specific genetic factors in cigarette smoking. Health Psychol
1999:18:14–20.
45 Batra A, Gelfort G, Bartels M, et al. The dopamine D2 receptor (DRD2)
gene – a genetic risk factor in heavy smoking? Addict Biol
2000;5:429–36.
46 Walton R, Johnstone E, Munafo M, et al. Genetic clues to the molecular
basis of tobacco addiction and progress towards personalised therapy.
Trends in Molecular Medicine 2001;7:70–6.
47 Munafo M, Johnstone E, Murphy M, et al. New directions in the genetic
mechanisms underlying nicotine addiction. Addict Biol 2001;6:109–17.
48 Swan GE. Implications of genetic epidemiology for the prevention of
tobacco use. Nicotine and Tobacco Research 1999;1:S49–56.
49 Risch N. Mapping genes for psychiatric disorders. In Gershon ES,
Cloninger CR, eds. Genetic approaches to mental disorders.Washington
DC:American Psychopathological Association, 1994.
50 Lichtenstein P, Holm NV, Versalko PK, et al. Environmental and
heritable factors in the causation of cancer: analyses of cohorts of twins
from Sweden, Denmark and Finland. N Engl J Med 2000;343:78–85.
51 Risch N. The genetic epidemiology of cancer: interpreting family and
twin studies and their implications for molecular genetic approaches.
Cancer Epidemiology, Biomarkers and Prevention 2001;10:733–41.
52 Bouchardy C, Benhamou S, Journekova N, et al. Metabolic genetic
polymorphisms and susceptibility to lung cancer. Lung Cancer
2000;32:109–12.
53 Devereux TR, Taylor JA, Barret JC. Molecular mechanisms of lung
cancer: interaction of environmental and genetic factors. Chest
1996;109:14S–19S.
54 Humphries SE, Talmud PJ, Hawe E, et al. Apolipoprotein E4 and
coronary heart disease in middle-aged men who smoke: a prospective
study. Lancet 2001;358:115–19.
55 Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary
disease. Respiratory Research 2001;2:20–6.
56 US Department of Health, Education, and Welfare. Smoking and
health. Report of the Advisory Committee to the Surgeon General of the
Public Health Service. Washington, DC: Public Health Service, 1964.
(PHS Publication No. 1103.)
57 Kitcher P. Abusing science: the case against creationism. Cambridge,
Massachusetts: MIT Press, 1983.
58 Collins FS. Shattuck lecture: medical and social consequences of the
Human Genome Project. N Engl J Med 1999;341:28–37.
59 Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic
testing. BMJ 2001;322:1052–6.
60 Holtzman NA, Marteau TM. Will genetics revolutionise medicine? N
Engl J Med 2000;343:141–4.
61 Holtzman NA, Shapiro D. Genetic testing and public policy. BMJ
1998;316:852–6.
62 Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of
genetic tests in populations. Lancet 2001;357:709–12.
63 Shine B. Nicotine vaccine moves toward clinical trials. NIDA Notes
2000;15:(5):1-2.
64 Wang XL, Mahaney MC. Geneotype-specific effects of smoking on risk
of CHD. Lancet 2001;358;87–8.
65 Degenhardt L, Hall W. The relationship between tobacco use,
substance-use disorders and mental health: results from the national
survey of mental health and well-being. Nicotine and Tobacco Research
2001;3:225–34.
66 Marteau TM, Croyle RT. Psychological responses to genetic testing. BMJ
1998;316:693–6.
67 World Health Organization. Guidelines for controlling and monitoring
the tobacco epidemic. Genetics: World Health Organization, 1998.
68 Genewatch UK. Patent on life warning as links between Biotech
companies and Japan Tobacco exposed. Access date 13 November
2001. URL: http://www.genewatch.org/press%20 Releases/pr20.htm/
124 Hall, Madden, Lynskey
www.tobaccocontrol.com
